



Optimizing inhaled therapies



Non-confidential company introductory presentation
May 2024

Company profile: what we do



VisionHealth is specialized in **Digital Therapeutics for Inhaled Medicines**.

We develop **patient-centric digital health solutions** targeting more **efficient inhaled drug delivery**, to provide better clinical outcomes for patients suffering from pulmonary diseases.

Our **licensed Kata®** application **redefines therapy adherence and disease management** for inhaled medicines.

Our **company** was founded in 2017 and is located in **Munich, Germany and Boston, USA**.

Management Team:

We know Respiratory drug delivery, Biotech and Digital health technology

Dr. Sabine Häussermann

Chief Executive Officer, Founder
Munich, Germany



30 years in respiratory drug delivery, digital health & clinical trial design

Philipp Kroneberg

Chief Operating Officer, Co-Founder
Munich, Germany



20 years in BD in respiratory medicine & in market access of telemedicine

Peter Shadday

President VisionHealth Inc.
Boston, USA



30 years in healthcare as commercial lead; marketing & market access,

Hannes Wetscher

Chief Finance Officer
Munich, Germany



30 years in healthcare as finance lead; CFO of startups



Management & Team combines Business Experience in Biotech and MedTech, in Software Development and AI, Expert Knowledge in Respiratory & Digital Medicine

Our Goal: Impact the future of respiratory medicine and inhaled drug therapies

600 Million

- Patients with respiratory diseases globally

\$31.5 bn Inhaled drug market

- US represents 50% of the market

Future growth drivers:

- Ageing populations (Asthma, COPD,...)
- New therapies in rare diseases (e.g. PAH, IPF,...)



The Problem: inhaled therapies are very effective, but devices are hard for patients to use

A High Unmet Medical Need with Inhaled therapies is the insufficient Dose Delivery of Inhaled Drug caused by Incorrect Inhalation Technique by patients

Quality Of Drug inhalation

Correct use of the inhalation device with right inhalation technique.

Quantity Of Drug delivery

Adherence to the dosing regimen




Up to **90% of patients do not perform their inhalation therapy correctly.**

50% of inhalations deliver no dose.



*It can be hard to use MDIs correctly. Even when using the best technique, **you may only get 25% of what comes out of the MDI into your lungs.** This amount is often still enough to treat your lung condition. However, **most people have such difficulty using an MDI that they get even less than 15% from each puff.***



Our Kata[®] solution: coaches patients to use Inhalers well and improve outcomes

Solution


Improved quality and quantity of inhaled drug delivery

- ✓ Kata[®] smartphone App improves inhalation technique and quality of drug delivery.
- ✓ Kata[®] remotely monitors and coaches patients to correctly use their inhalers.
- ✓ AI algorithms of Kata[®] score inhalation technique and guide patients.
- ✓ Easily adaptable to all inhaler types (MDI, SMI, DPI).
- ✓ Kata[®] App offers features to make disease management easy for patients and healthcare providers.



Results

Patients experience better outcome

- ✓ Full therapeutic dose delivery leads to better outcomes & less complications
- 
- The diagram shows a human head in profile with a blue line representing the airway leading to the lungs. The lungs are yellow and show a high concentration of blue dots, indicating high drug deposition. A text box next to the diagram says: 'High drug deposition in the lung thanks to correct technique'.
- ✓ The Kata[®] app eliminates critical inhalation errors
 - ✓ Patients of all ages & background like Kata[®] resulting in high adherence.

Kata® in practice




Video demonstration of Kata® YouTube link:
<https://youtu.be/HC34qo8pK3g>



Adherence redefined


- > Real-time inhalation coach & animated guidance for any inhaler.
- > Video and auditory sensors measure quality of inhalation and correct dose delivery to the lungs.
- > Addresses handling errors and poor inhalation.
- > Maximizes therapy outcome.



Adherence Redefined and Disease Management beyond Inhalation Coaching



Current
Status



6 Clinical trials & usability studies, 1 Phase 3 study in Asthma (KaRe)



14 000 downloads



Available on IOS and Android



1500 active users in Germany




CE Class IIa (MDR) & ISMS ISO 27001
FDA Class 1 device

Kata® can be customized to every inhaler and disease with simple software adjustments

Medication frequency/
dosage & Inhalation score

Clinical value & Medical
questionnaires

Trends, settings, knowledges



Kata® offers many remote patient monitoring features which can be shared with HCPs and patient portals

Inhalation adherence graph


Exercise module (coming soon)

Mood score & comments


Our References




Summary



Poor inhaler technique and poor adherence lead to poor clinical outcome, caused by low/no drug deposition.



With Kata® the target drug dose is delivered at every inhalation with personalized, real-time coaching.



Katas AI algorithm can be easily adapted to each inhaler. Kata® offers many other remote patient monitoring features.



Together we can help patients achieve better outcomes by providing a more direct disease management option and empower them.

WE LOOK FORWARD TO HEARING FROM YOU

Digital therapeutics changes the way we deliver healthcare to patients.

VisionHealth GmbH
Landsberger Straße 72
80339 Munich
Germany

Peter Shadday
+1 857 243 0728

peter.shadday@visionhealth.gmbh
www.visionhealth.gmbh



REFERENCES DRUG DELIVERY TO THE LUNGS

- Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. *Cochrane Database Syst Rev*. 2017 Mar 13;3(3):CD012286. doi: 10.1002/14651858.CD012286.pub2. PMID: 28288272; PMCID: PMC6473469.
- Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. *Respir Care*. 2005 Oct;50(10):1360-74; discussion 1374-5. PMID: 16185371.
- Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. *Int J Chron Obstruct Pulmon Dis*. 2016 Mar 21;11:597-602. doi: 10.2147/COPD.S103335. PMID: 27051283; PMCID: PMC4807897.
- Sulaiman I, Greene G, MacHale E, Seheult J, Mokoka M, D'Arcy S, Taylor T, Murphy DM, Hunt E, Lane SJ, Diette GB, FitzGerald JM, Boland F, Sartini Bhreathnach A, Cushen B, Reilly RB, Doyle F, Costello RW. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. *Eur Respir J*. 2018 Jan 4;51(1):1701126. doi: 10.1183/13993003.01126-2017. PMID: 29301919.
- O'Dwyer S, Greene G, MacHale E, Cushen B, Sulaiman I, Boland F, Bosnic-Anticevich S, Mokoka MC, Reilly RB, Taylor T, Ryder SA, Costello RW. Personalized Biofeedback on Inhaler Adherence and Technique by Community Pharmacists: A Cluster Randomized Clinical Trial. *J Allergy Clin Immunol Pract*. 2020 Feb;8(2):635-644. doi: 10.1016/j.jaip.2019.09.008. Epub 2019 Sep 27. PMID: 31568927.
- Morton RW, Elphick HE, Rigby AS, Daw WJ, King DA, Smith LJ, Everard ML. STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma. *Thorax*. 2017 Apr;72(4):347-354. doi: 10.1136/thoraxjnl-2015-208171. Epub 2016 Nov 4. PMID: 27815524.
- Duerden, M., Price, D. Training Issues in the Use of Inhalers. *Dis-Manage-Health-Outcomes* 9, 75–87 (2001). <https://doi.org/10.2165/00115677-200109020-00002>
- Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respir Med*. 2008 Apr;102(4):593-604. doi: 10.1016/j.rmed.2007.11.003. Epub 2007 Dec 20. PMID: 18083019.
- Takaku Y, Kurashima K, Ohta C, Ishiguro T, Kagiya N, Yanagisawa T, Takayanagi N. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? *Respir Med*. 2017 Feb;123:110-115. doi: 10.1016/j.rmed.2016.12.012. Epub 2016 Dec 21. PMID: 28137486.
- Inhaler Error Steering Committee; Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, Scheuch G, Bousquet J. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. *Respir Med*. 2013 Jan;107(1):37-46. doi: 10.1016/j.rmed.2012.09.017. Epub 2012 Oct 23. PMID: 23098685.
- Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. *Respir Med*. 2013 Oct;107(10):1481-90. doi: 10.1016/j.rmed.2013.04.005. Epub 2013 May 3. PMID: 23643487.
- Hale EM, Greene G, Mulvey C, Mokoka MC, van Boven JFM, Cushen B, Sulaiman I, Brennan V, Lombard L, Walsh J, Plunkett S, McCartan TA, Kerr PJ, Reilly RB, Hughes C, Kent BD, Jackson DJ, Butler M, Counihan I, Hayes J, Faul J, Kelly M, Convery R, Nanzer AM, Fitzgerald JM, Murphy DM, Heaney LG, Costello RW; INCA Research Team. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. *Lancet Respir Med*. 2023 Jul;11(7):591-601. doi: 10.1016/S2213-2600(22)00534-3. Epub 2023 Mar 21. Erratum in: *Lancet Respir Med*. 2023 May;11(5):e47. PMID: 36963417.
- van de Hei SJ, Kim CH, Honkoop PJ, Sont JK, Schemer TRJ, MacHale E, Costello RW, Kocks JWH, Postma MJ, van Boven JFM. Long-term cost-effectiveness of digital inhaler adherence technologies in difficult-to-treat asthma. *J Allergy Clin Immunol Pract*. 2023 Jul 3:S2213-2198(23)00716-X. doi: 10.1016/j.jaip.2023.06.051. Epub ahead of print. PMID: 37406806.